Skip to main content

School of Life Sciences

VirionHealth Raises Series A Funding from Abingworth

Laura Lane, Profs Easton and DimmockVirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has raised up to £13 million in Series A funding from Abingworth, the international investment group dedicated to life sciences.

VirionHealth, founded on pioneering research by Professors Nigel Dimmock and Andrew Easton at the School of Life Sciences, is a world leader in the development of precisely engineered, non-infectious, defective interfering particles. This new class of biological antiviral acts by outcompeting replication of infectious viruses to both prevent and treat viral infections.

Public Science evenings

Tuesday 28 November: The ocean bacteria that control the world! - led by Dr Joseph Christie-Oleza.
Tuesday 16 January: When the pandemic strikes! - led by Professor Matt Keeling and Mike Tildesley.
Tuesday 13 March: Is the brain the only part of the body that named itself? A biological panel discussion - led by Professor Nicholas Dale.

 

bronze.pngThe School of Life Sciences has been recognised for its commitment to Athena SWAN in the achievement of a Bronze Award in 2013. This was renewed in April 2015 for a further three years.

"Athena SWAN is a central component of our culture and working practice and we continue to champion the development of a science department that provides collegiality and transparency to ensure equal opportunities for all"
Head of School, Professor Lorenzo Frigerio

SLS Athena SWAN webpage

Impact

Researchers in the School of Life Sciences are developing state-of-the-art devices that can be used as rapid and accurate diagnostic tools by clinicians.

Biosensor Innovation

Biosensors for emergency clinical diagnosis

More than 80% of research in the School was rated as ‘world leading’ or ‘internationally excellent’ in REF2014

Twitter